Kura Oncology Announces Four Abstracts Accepted for Presentation at ASH Annual Meeting
Kura Oncology Announces Four Abstracts Accepted for Presentation at ASH Annual Meeting
11-03-2022
“We are honored that several abstracts showcasing our menin inhibitor program have been selected for presentation, including an oral presentation of updated data from our KOMET-001 trial of ziftomenib in relapsed/refractory acute myeloid leukemia,” said
Session titles and information for the four abstracts are listed below and are now available on the ASH online itinerary planner.
Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Session
Session Date and Time:
Oral Presentation Time:
Location:
Publication Number: 64
Preclinical In
Session
Session Date and Time:
Location:
Publication Number: 1516
The Menin Inhibitor Ziftomenib (KO-539) Synergizes with Agents Targeting Chromatin Regulation or Apoptosis and Sensitizes AML with MLL Rearrangement or NPM1 Mutation to Venetoclax
Session
Session Date and Time:
Location:
Publication Number: 2770
Novel Combination of Clinical Menin Inhibitor Ziftomenib and the Nuclear Export Inhibitor Selinexor Synergistically Inhibit MLL-r AML
Session
Session Date and Time:
Location:
Publication Number: 3969
Copies of the presentations will be available on Kura's website at www.kuraoncology.com/pipeline/publications/ following presentation at the meeting.
About
Forward-Looking Statements
This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and therapeutic potential of ziftomenib, and the opportunity of the KOMET-001 trial to make a substantial impact in improving patient outcomes in acute myeloid leukemia. Factors that may cause actual results to differ materially include the risk that compounds that appeared promising in early research or clinical trials do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Kura may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings, applications and other interactions with regulatory bodies, risks associated with reliance on third parties to successfully conduct clinical trials, the risks associated with reliance on outside financing to meet capital requirements, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “promise,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to the Company's periodic and other filings with the
Contacts
Company:
Senior Vice President, Investor Relations &
Corporate Communications
(858) 500-8803
pete@kuraoncology.com
Investors:
Managing Director
ICR Westwicke
(858) 356-5932
robert.uhl@westwicke.com
Media:
Managing Director
Evoke Canale
(619) 849-6005
jason@canalecomm.com
Source: Kura Oncology, Inc.